文献速递眼底病与葡萄膜炎

非诺贝特使用与进展为视力威胁性糖尿病视网膜病变风险的关联

Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

这项多中心队列研究利用美国大型保险公司的医疗索赔数据,纳入5835例基线非增殖性糖尿病视网膜病变(NPDR)的非诺贝特使用者和144417例非使用者。多变量Cox回归显示,非诺贝特使用与视力威胁性糖尿病视网膜病变(VTDR)风险降低(HR 0.92)和增殖性糖尿病视网膜病变(PDR)风险降低(HR 0.76)相关,但与糖尿病黄斑水肿(DME)风险无显著关联(HR 0.96)。作者认为这些发现支持开展进一步临床试验以确定因果关系的合理性。

要点

  • 非诺贝特使用与VTDR风险降低相关(HR 0.92,95%CI 0.87-0.98;P=0.01)。
  • 非诺贝特使用与PDR风险降低相关(HR 0.76,95%CI 0.64-0.90;P=0.001)。
  • 非诺贝特使用与DME风险无显著关联(HR 0.96,95%CI 0.90-1.03;P=0.27)。

核心结论

  • 本研究中,非诺贝特使用与PDR和VTDR风险降低相关,但与单纯DME无显著关联。
  • 这些发现支持开展进一步临床试验,以确定非诺贝特使用与PDR或VTDR风险降低之间的关联是否可能代表因果关系。

研究设计与样本

  • 多中心队列研究,使用美国大型保险公司的医疗索赔数据。
  • 队列纳入2002年1月1日至2019年6月30日期间有实验室检查值的18岁及以上NPDR患者。
  • 排除标准包括既往诊断PDR、DME、增殖性玻璃体视网膜病变或曾接受VTDR治疗;无论NPDR何时在保险计划中首次记录,纳入保险计划2年内诊断VTDR者亦被排除。
  • 暴露为非诺贝特使用;主要结局为新诊断VTDR(PDR或DME的复合结局)以及分别诊断的DME和PDR。
  • 采用多变量Cox比例风险回归,所有协变量均使用时间更新模型;协变量包括NPDR严重程度量表、系统性疾病、人口学特征、肾功能(基于估算肾小球滤过率水平)、糖化血红蛋白、血红蛋白和胰岛素使用。

主要发现

  • 共纳入5835例基线NPDR的非诺贝特使用者(平均[SD]年龄65.3[10.4]岁;3564例[61.1%]男性;3024例[51.8%]白人)和144417例非诺贝特非使用者(平均[SD]年龄65.7[12.3]岁;73587例[51.0%]男性;67023例[46.4%]白人)。
  • 在这些患者中,27325例(18.2%)进展为VTDR,4086例(2.71%)进展为PDR,22750例(15.1%)进展为DME。
  • 控制所有协变量后,Cox模型结果显示非诺贝特与VTDR风险降低相关(HR 0.92,95%CI 0.87-0.98;P=0.01)。
  • 控制所有协变量后,Cox模型结果显示非诺贝特与PDR风险降低相关(HR 0.76,95%CI 0.64-0.90;P=0.001)。
  • 控制所有协变量后,Cox模型结果显示非诺贝特与DME风险无显著关联(HR 0.96,95%CI 0.90-1.03;P=0.27)。

关键数值与推荐

  • 非诺贝特使用与VTDR风险降低相关(HR 0.92,95%CI 0.87-0.98;P=0.01)。
  • 非诺贝特使用与PDR风险降低相关(HR 0.76,95%CI 0.64-0.90;P=0.001)。
  • 非诺贝特使用与DME风险无显著关联(HR 0.96,95%CI 0.90-1.03;P=0.27)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Diabetic retinopathy (DR) may progress from nonproliferative DR (NPDR) to vision-threatening DR (VTDR). Studies have investigated fenofibrate use as a protective measure with conflicting results, and fenofibrate is not typically considered by ophthalmologists in the management of DR currently. OBJECTIVE: To assess the association between fenofibrate use and the progression from NPDR to VTDR, proliferative DR (PDR), or diabetic macular edema (DME). DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study used medical claims data from a large US insurer. Cohorts were created from all patients with NPDR 18 years or older who had laboratory values from January 1, 2002, to June 30, 2019. Exclusion criteria consisted of any previous diagnosis of PDR, DME, proliferative vitreoretinopathy, or treatment used in the care of VTDR. Patients were also excluded if they had a diagnosis of VTDR within 2 years of insurance plan entry, regardless of when NPDR was first noted in the plan. EXPOSURES: Fenofibrate use. MAIN OUTCOMES AND MEASURES: The main outcomes were a new diagnosis of VTDR (a composite outcome of either PDR or DME) or DME and PDR individually. A time-updating model for all covariates was used in multivariate Cox proportional hazard regression to determine hazards of progressing to an outcome. Additional covariates included NPDR severity scale, systemic illnesses, demographics, kidney function (based on estimated glomerular filtration rate level), hemoglobin A1c, hemoglobin, and insulin use. RESULTS: A total of 5835 fenofibrate users with NPDR at baseline (mean [SD] age, 65.3 [10.4] years; 3564 [61.1%] male; 3024 [51.8%] White) and 144 417 fenofibrate nonusers (mean [SD] age, 65.7 [12.3] years; 73 587 [51.0%] male; 67 023 [46.4%] White) were included for analysis. Of these, 27 325 (18.2%) progressed to VTDR, 4086 (2.71%) progressed to PDR, and 22 750 (15.1%) progressed to DME. After controlling for all covariates, Cox model results showed fenofibrates to be associated with a decreased risk of VTDR (hazard ratio, 0.92 [95% CI, 0.87-0.98]; P = .01) and PDR (hazard ratio, 0.76 [95% CI, 0.64-0.90]; P = .001) but not DME (hazard ratio, 0.96 [95% CI, 0.90-1.03]; P = .27). CONCLUSIONS AND RELEVANCE: In this study, fenofibrate use was associated with a decreased risk of PDR and VTDR but not DME alone. These findings support the rationale for additional clinical trials to determine if these associations may be representative of a causal relationship between fenofibrate use and reduced risk of PDR or VTDR.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Meer E, Bavinger JC, Yu Y, et al. Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy. JAMA Ophthalmol. 2022. PMID: 35389455. doi:10.1001/jamaophthalmol.2022.0633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。